Tesofensine (NS 2330) is a potent triple monoamine reuptake inhibitor (SNDRI) primarily researched for its robust effects on metabolic health and neurochemical signaling. It’s an appetite suppressant and helps for weight management.

Key Features

• Triple Action Mechanism: It simultaneously inhibits the reuptake of serotonin, norepinephrine, and dopamine.This broad interaction makes it significantly more effective for appetite suppression than single-target agents.
  
  
• Robust Satiety Induction: Indirectly stimulates alpha-1 adrenoceptors and dopamine D1 receptors, which are key pathways for managing food-seeking behavior and satiety.
  
  
• Long Duration of Action: Features an exceptionally long half-life of approximately 9 days (220 hours), allowing for stable levels and minimizing fluctuations between doses.
  
  
• Metabolic Enhancement: Beyond appetite control, it is studied for its ability to increase resting energy expenditure and improve fat oxidation.
  
  
• Clinical Efficacy: Demonstrated weight loss results in clinical trials (TIPO-1) that are competitive with top-tier injectable GLP-1 analogs, despite being an oral agent.
  
  

Technical Specifications

Available Configurations

In the research and laboratory procurement market, Tesofensine is generally available in the following formats:

• Oral Capsules (Research Supply):
• 60ct Bottles: Often configured at 250 mcg (0.25 mg) or 500 mcg (0.5 mg) per capsule.
• 30ct Bottles: Commonly used for shorter-term longitudinal studies.
• Bulk Lyophilized Powder:
• Available in 50mg, 100mg, and 500mg vials for laboratory researchers who need to create custom concentrations or solutions for in-vitro or in-vivo testing.
• Reference Standards:
• Highly purified units (e.g., 5mg or 10mg) typically provided by chemical supply houses like Cayman Chemical or MedChemExpress for analytical verification.